Skip to product information
1 of 2

IGFBP-6 Protein, Human

IGFBP-6 Protein, Human

Catalog Number: UA040588 Brand: UA BIOSCIENCE
Price:
Regular price $120 USD
Regular price Sale price $120 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Human
Synonyms Insulin-like growth factor-binding protein 6, IBP-6, IGF-binding protein 6, IGFBP-6
Accession P24592
Amino Acid Sequence

Arg28-Gly240, with His at C-terminus

Expression System HEK293
Molecular Weight

35-40 kDa (Reducing)

Endotoxin <0.1EU/μg
Conjugation Unconjugated
Tag His Tag
Physical Appearance Lyophilized Powder
Reconstitution

Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation

Stability & Storage

·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.

·3 months, -20 to -80℃ under sterile conditions after reconstitution.

·1 week, 2 to 8℃ under sterile conditions after reconstitution.

·Please avoid repeated freeze-thaw cycles.

Background

Insulin-like Growth Factor Binding Protein-6 (IGFBP-6) is a 30-kDa secreted glycoprotein encoded by the Igfbp6 gene, distinguished by its extraordinary ~50–70-fold binding preference for IGF-II over IGF-I. This selectivity is mediated by cooperative interactions between the N-terminal subdomain and C-terminal domain of IGFBP-6 with adjacent binding sites on IGF-II. IGFBP-6 primarily functions as a selective inhibitor of IGF-II actions, blocking IGF-II-induced cell proliferation, differentiation, migration, and survival across diverse cell types including myoblasts, neuroblastoma cells, and rhabdomyosarcoma cells. Unlike other IGFBPs, it has minimal effect on IGF-I activity.

IGFBP-6 expression is developmentally regulated in mouse skeletal muscle, with high levels during embryogenesis and sustained expression in adult muscle tissue.

Picture

Bioactivity

Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF‑7 human breast cancer cells. The IC50 is 8.0-91 ng/mL in the presence of 14 ng/mL human IGF-II.

SDS-PAGE

2μg (R: reducing condition, N: non-reducing condition).